BIT:RECPharmaceuticals
Recordati (BIT:REC) Margin Slippage Tests Bullish Rare Disease Expansion Narrative
Recordati Industria Chimica e Farmaceutica (BIT:REC) has put solid numbers on the table for FY 2025, with fourth quarter revenue of €662.2 million and basic EPS of €0.57, supported by trailing 12 month revenue of €2.6 billion and EPS of €2.16. The company has seen quarterly revenue move between €598.5 million and €679.9 million over the past six reported periods, while basic EPS has ranged from €0.38 to €0.61. This gives investors a clear view of how earnings track the top line ahead of what...